The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Anastrozole Is Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer in Postmenopausal Women: Results of a North American Multicenter Randomized Trial
Abstract
PURPOSE: The efficacy and tolerability of anastrozole (Arimidex; AstraZeneca, Wilmington, DE, and Macclesfield, United Kingdom) and tamoxifen were compared as first-line therapy for advanced breast cancer in 353 postmenopausal women. PATIENTS AND METHODS: The randomized, double-blind, multicenter study was designed to evaluate anastrozole 1 mg once daily relative to tamoxifen 20 mg once daily in patients with hormone receptor–positive tumors or tumors of unknown receptor status who were eligible for endocrine therapy. Primary end points were objective response (OR), defined as complete (CR) or partial (PR) response, time to progression (TTP), and tolerability. RESULTS: Anastrozole was as effective as tamoxifen in terms of OR (21% v 17% of patients, respectively), with clinical benefit (CR + PR + stabilization ≥ 24 weeks) observed in 59% of patients on anastrozole and 46% on tamoxifen (two-sided P = .0098, retrospective analysis). Anastrozole had a significant advantage over tamoxifen in terms of TTP (median TTP of 11.1 and 5.6 months for anastrozole and tamoxifen, respectively; two-sided P = .005). The tamoxifen:anastrozole hazards ratio was 1.44 (lower one-sided 95% confidence limit, 1.16). Both treatments were well tolerated. However, thromboembolic events and vaginal bleeding were reported in fewer patients who received anastrozole compared with those who received tamoxifen (4.1% v 8.2% [thromboembolic events] and 1.2% v 3.8% [vaginal bleeding], respectively). CONCLUSION: Anastrozole satisfied the predefined criteria for equivalence to tamoxifen. Furthermore, we observed both a significant increase in TTP and a lower incidence of thromboembolic events and vaginal bleeding with anastrozole. These findings indicate that anastrozole should be considered as first-line therapy for postmenopausal women with advanced breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1371 · Cited by 5,485
Tamoxifen for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(97)11423-4 · Cited by 4,085
Polychemotherapy for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(98)03301-7 · Cited by 2,042
Fisher, B., Dignam, J., Bryant, J., DeCillis, A., Wickerham, D. L., Wolmark, N., Costantino, J., Redmond, C., Fisher, E. R., Bowman, D. M., et al. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.21.1529 · Cited by 861
Bonneterre, J., Thürlimann, B., Robertson, J. F. R., Krzakowski, M., Mauriac, L., Koralewski, P., Vergote, I., Webster, A., Steinberg, M., & von Euler, M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.22.3748 · Cited by 842
Self-citationAssessment of response to therapy in advanced breast cancer
Hayward, J. L., Carbone, P. P., Heusen, J. C., Kumaoka, S., Segaloff, A., & Rubens, R. D. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.42 · Cited by 705
Dombernowsky, P., Smith, I., Falkson, G., Leonard, R., Panasci, L., Bellmunt, J., Bezwoda, W., Gardin, G., Gudgeon, A., Morgan, M., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.453 · Cited by 638
Hayward, J. L., Carbone, P. P., Heuson, J.-C., Kumaoka, S., Segaloff, A., & Rubens, R. D. (1977) · Cancer · doi:10.1002/1097-0142(197703)39:3<1289::aid-cncr2820390340>3.0.co;2-f · Cited by 623
Fossati, R., Confalonieri, C., Torri, V, Ghislandi, E., Penna, A., Pistotti, V, Tinazzi, A., & Liberati, A. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.10.3439 · Cited by 546
Buzdar, A. U., Jonat, W., Howell, A., Jones, S. E., BLOMQVIST, C. P., Vogel, C. L., EIERMANN, W., Wolter, J. M., Steinberg, M., Webster, A., et al. (1998) · PubMed · Cited by 417
Self-citationUse of tamoxifen for breast cancer: twenty-eight years later.
Jaiyesimi, I. A., Buzdar, A. U., Decker, D. A., & Hortobagyi, G. N. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.2.513 · Cited by 413
Self-citationBuzdar, A., Jonat, W., Howell, A., Jones, S. E., Blomqvist, C., Vogel, C. L., Eiermann, W., Wolter, J. M., Azab, M., Webster, A., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.7.2000 · Cited by 406
Geisler, J., King, N., Dowsett, M., Ottestad, L., Lundgren, S., Walton, P., Kormeset, P., & Lønning, P. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.531 · Cited by 336
Ingle, J. N., Ahmann, D. L., Green, S. J., Edmonson, J. H., Bisel, H. F., Kvols, L. K., Nichols, W. C., Creagan, E. T., Hahn, R. G., Rubin, J., et al. (1981) · New England Journal of Medicine · doi:10.1056/nejm198101013040104 · Cited by 336
Hayes, D. F., Van Zyl, J. A., Hacking, A., Goedhals, L., Bezwoda, W. R., Mailliard, J. A., Jones, S. E., Vogel, C. L., Berris, R. F., & Shemano, I. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.10.2556 · Cited by 216
Arimidex Study Group, Buzdar, A. U., Jonat, W., Howell, A., Jones, S. E., Blomqvist, C. P., Vogel, C. L., Eiermann, W., Wolter, J. M., Steinberg, M., et al. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980915)83:6<1142::aid-cncr13>3.0.co;2-5 · Cited by 174
Self-citationExperimental and clinical results with intraperitoneal cisplatin.
Huinink, W. W. T. B., Dubbelman, R., Aartsen, E. J., Franklin, H. L., & Jg, M. (1985) · PubMed · Cited by 148
Buzdar, A. U., Smith, R. A., Vogel, C. L., Bonomi, P., Keller, A. M., Favis, G., Mulagha, M. T., Cooper, J., & for the Multi-Institutional Trialist Collaborative Study Group (1996) · Cancer · Cited by 118
Self-citationHowell, A., Mackintosh, J., Jones, M., Redford, J., Wagstaff, J., & Sellwood, R. A. (1988) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(88)90046-6 · Cited by 106
Carrion, R. P., Candel, V. A., Calabresi, F., Michel, R. T., dos Santos, R. B., Delozier, T., Goss, P. E., Mauriac, L., Feuilhade, F., & Freue, M. (1994) · PubMed · Cited by 99
Toremifene and tamoxifen in advanced breast cancer - a double-blind cross-over trial
Stenbygaard, L. E., Herrstedt, J., Thomsen, J. F., et al. (1993) · Breast Cancer Research and Treatment · doi:10.1007/bf00662401 · Cited by 95
Thurlimann, B. J. K., Beretta, K., Bacchi, M., Castiglione‐Gertsch, M., Goldhirsch, A., Jungi, W. F., Cavalli, F., Senn, H.-J., Fey, M. F., & Löhnert, T. (1996) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a010635 · Cited by 95
Smith, I. E., Harris, A. L., Morgan, M., Gazet, J. C., & McKinna, J. A. (1982) · PubMed · Cited by 92
Aromatase inhibitors in advanced breast cancer: mechanism of action and clinical implications
Brodie, A. M. H., & Njar, V. C. O. (1998) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(98)00022-3 · Cited by 88
Muss, H. B., Wells, H. B., Paschold, E., Black, W. R., Cooper, M. R., Capizzi, R. L., Christian, R., Cruz, J. M., Jackson, D. V., & Powell, B. L. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.7.1098 · Cited by 77
Ingle, J. N., Ahmann, D. L., Green, S., Edmonson, J. H., Creagan, E. T., Hahn, R. G., & Rubin, J. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198204000-00062 · Cited by 73
Robertson, J. F. R., Williams, M. R., Todd, J. H., Nicholson, R. I., Morgan, D. A. L., & Blamey, R. W. (1989) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(89)90259-9 · Cited by 72
Muss, H. B., Case, L. D., Atkins, J., Bearden, J. D., Cooper, M. R., Cruz, J. M., Jackson, D. V., O’Rourke, M. A., Pavy, M. D., & Powell, B. L. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.8.1630 · Cited by 70
Falkson, C. I., & Hc, F. (1996) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a010634 · Cited by 66
Miller, W. R. (1996) · Endocrine Related Cancer · doi:10.1677/erc.0.0030065 · Cited by 53
Gill, P. G., Gebski, V., Snyder, R. D., Burns, I., Levi, J. A., Byrne, M., & Coates, A. S. (1993) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a058658 · Cited by 44
Robertson, J. F. R., Howell, A., Buzdar, A. U., von Euler, M., & Lee, D. (1999) · Breast Cancer Research and Treatment · doi:10.1023/a:1006391902868 · Cited by 40
Self-citationTamoxifen and fluoxymesterone in advanced breast cancer: a controlled clinical trial.
Westerberg, H. (1980) · PubMed · Cited by 29
Gockerman, J. P., Spremulli, E. N., Raney, M. R., & Logan, T. F. (1986) · PubMed · Cited by 28
Paterson, A. H., Hanson, J., Pritchard, K. I., Sansregret, E., Dahrouge, S., McDermot, R. S. R., Fine, S., Df, W., Trudeau, M., & Dj, S. (1990) · PubMed · doi:10.5555/uri:pii:009377549090009r · Cited by 25
Aromatase inhibitors and their future role in post-menopausal women with early breast cancer
Lønning, P. E. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.756 · Cited by 21
Research works printed but not linked: 7
- 10.1002/1097-0142(19940115)73:2<354::AID-CNCR2820730220>3.0.CO;2-J · doi:10.1002/1097-0142(19940115)73:2<354::aid-cncr2820730220>3.0.co;2-j
- 10.1016/S0959-8049(97)00178-0 · doi:10.1016/s0959-8049(97)00178-0
- Stuart NSA, Warwick J, Blackledge GRP, et al: A randomized phase III cross-over study of tamoxifen versus megestrol acetate in advanced and recurrent breast cancer. Eur J Cancer 32A: 1888,1996-1892, · doi:10.1016/0959-8049(96)00191-8
- 10.1002/1097-0142(19860701)58:1<7::AID-CNCR2820580103>3.0.CO;2-# · doi:10.1002/1097-0142(19860701)58:1<7::aid-cncr2820580103>3.0.co;2-#
- 10.1093/oxfordjournals.annonc.a058657 · doi:10.1093/oxfordjournals.annonc.a058657
- 10.1002/1097-0142(19871115)60:10<2376::AID-CNCR2820601005>3.0.CO;2-N · doi:10.1002/1097-0142(19871115)60:10<2376::aid-cncr2820601005>3.0.co;2-n
- 10.1002/(SICI)1097-0142(19960615)77:12<2503::AID-CNCR13>3.0.CO;2-W · doi:10.1002/(sici)1097-0142(19960615)77:12<2503::aid-cncr13>3.0.co;2-w
Cited by
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
Benson, A. B., Abrams, T. A., Ben-Josef, E., Bloomston, P. M., Botha, J. F., Clary, B. M., Covey, A., Curley, S. A., D'Angelica, M. I., Davila, R., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0027 · Cited by 2,268
Cuzick, J., Sestak, I., Baum, M., Buzdar, A., Howell, A., Dowsett, M., & Forbes, J. F. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70257-6 · Cited by 1,674
Self-citationBreast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C., Elias, A. D., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0016 · Cited by 1,584
Metadata
- Authors
- Nabholtz, J. M., Buzdar, A., Pollak, M., Harwin, W., Burton, G., Mangalik, A., Steinberg, M., Webster, A., & von Euler, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2000-11-15
- Volume
- 18
- Issue
- 22
- Pages
- 3758-3767
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1932574503
- Cited by
- 992
- References
- 36
- FWCI
- 31.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.